These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 1998982)

  • 1. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
    Grunewald R; Abbruzzese JL; Tarassoff P; Plunkett W
    Cancer Chemother Pharmacol; 1991; 27(4):258-62. PubMed ID: 1998982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.
    Grunewald R; Kantarjian H; Du M; Faucher K; Tarassoff P; Plunkett W
    J Clin Oncol; 1992 Mar; 10(3):406-13. PubMed ID: 1740680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.
    Grunewald R; Kantarjian H; Keating MJ; Abbruzzese J; Tarassoff P; Plunkett W
    Cancer Res; 1990 Nov; 50(21):6823-6. PubMed ID: 2208147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
    Abbruzzese JL; Grunewald R; Weeks EA; Gravel D; Adams T; Nowak B; Mineishi S; Tarassoff P; Satterlee W; Raber MN
    J Clin Oncol; 1991 Mar; 9(3):491-8. PubMed ID: 1999720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
    Ruiz van Haperen VW; Veerman G; Boven E; Noordhuis P; Vermorken JB; Peters GJ
    Biochem Pharmacol; 1994 Oct; 48(7):1327-39. PubMed ID: 7945430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
    Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
    Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
    Heinemann V; Xu YZ; Chubb S; Sen A; Hertel LW; Grindey GB; Plunkett W
    Cancer Res; 1992 Feb; 52(3):533-9. PubMed ID: 1732039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
    Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
    J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
    Heinemann V; Hertel LW; Grindey GB; Plunkett W
    Cancer Res; 1988 Jul; 48(14):4024-31. PubMed ID: 3383195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new, simple method for quantifying gemcitabine triphosphate in cancer cells using isocratic high-performance liquid chromatography.
    Nishi R; Yamauchi T; Ueda T
    Cancer Sci; 2006 Nov; 97(11):1274-8. PubMed ID: 17034368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
    van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
    Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome.
    Jiang HY; Hickey RJ; Abdel-Aziz W; Malkas LH
    Cancer Chemother Pharmacol; 2000; 45(4):320-8. PubMed ID: 10755321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
    Touroutoglou N; Gravel D; Raber MN; Plunkett W; Abbruzzese JL
    Ann Oncol; 1998 Sep; 9(9):1003-8. PubMed ID: 9818075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
    Khatri A; Williams BW; Fisher J; Brundage RC; Gurvich VJ; Lis LG; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK; Kirstein MN
    Br J Cancer; 2014 Jan; 110(2):304-12. PubMed ID: 24300978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
    Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
    J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
    Huang P; Chubb S; Hertel LW; Grindey GB; Plunkett W
    Cancer Res; 1991 Nov; 51(22):6110-7. PubMed ID: 1718594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
    Veltkamp SA; Jansen RS; Callies S; Pluim D; Visseren-Grul CM; Rosing H; Kloeker-Rhoades S; Andre VA; Beijnen JH; Slapak CA; Schellens JH
    Clin Cancer Res; 2008 Jun; 14(11):3477-86. PubMed ID: 18519780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
    van Moorsel CJ; Bergman AM; Veerman G; Voorn DA; Ruiz van Haperen VW; Kroep JR; Pinedo HM; Peters GJ
    Biochim Biophys Acta; 2000 Mar; 1474(1):5-12. PubMed ID: 10699484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
    Hodge LS; Taub ME; Tracy TS
    Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
    Bouffard DY; Laliberté J; Momparler RL
    Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.